CVS reportedly in talks to buy Aetna

The Wall Street Journal reported a $66 billion deal is being discussed as CVS looks to bolster itself in preparation for Amazon's potential entry into the drug distribution business.

By Shannon Muchmore • Oct. 27, 2017

Neos stock shoots up after PDL makes all-cash offer public

After several attempts to quietly acquire Neos, PDL is taking its offer hostile in hopes of swaying shareholders. 

By Suzanne Elvidge • Oct. 27, 2017

Incyte pays $150M to bolster combo strategy

Through a deal with MacroGenics, Incyte is adding a second checkpoint inhibitor to its pipeline to test in combination with its slate of immunotherapies.

By Lisa LaMotta • Oct. 25, 2017

AbbVie taps Alector for deeper dive into Alzheimer's

As research into the immune system booms, the two companies will investigate treatments that aim to use the body's defenses to fight neurodegenerative disorders.

By Jacob Bell • Oct. 25, 2017

Reader poll: Pfizer most likely buyer for Spark

When asked what company would be most interested in the gene therapy drugmaker, BioPharma Dive readers had mixed feelings, but Pfizer won out. 

By Lisa LaMotta • Oct. 25, 2017

Biogen doubling down on aducanumab

The big biotech is paying $150 million to reclaim 15% of the Alzheimer's candidate's potential royalties, and may take the agreement one step further.

By Jacob Bell • Oct. 24, 2017

Finch, Crestovo merger pushes forward C diff therapeutic

The combination of two microbiota-based companies could help make microbe-based treatments mainstream.

By Suzanne Elvidge • Oct. 24, 2017

Eisai shows confidence in Biogen's Alzheimer's drug

The Japanese pharma expanded its deal with the big biotech around the closely-watched Alzheimer's disease drug aducanumab. 

By Lisa LaMotta • Oct. 23, 2017

What's next for biopharma Q3 earnings

Bristol-Myers, AbbVie, Merck, Gilead and several other notable names will all host third quarter earnings calls this week.

By Ned Pagliarulo , Lisa LaMotta , Jacob Bell • Oct. 20, 2017

Prescribed Reading: Blockbuster potential thwarted; generics consolidate

The past week saw multiple companies discontinue development of potential blockbusters, while a tightening generics market prompted a new merger.

By Lisa LaMotta • Oct. 20, 2017

Arcturus expands partnership with J&J into hepatitis B

On the verge of going public through a reverse merger, Arcturus locks down its second partnership with the big pharma. 

By Suzanne Elvidge • Oct. 20, 2017

Scangos' new biotech tackling infectious disease

Deals with Alnylam and Visterra help Vir build out its pipeline.

By Jacob Bell • Oct. 19, 2017

Anthem leaves Express Scripts behind to roll out its own PBM

Named IngenioRx, the new pharma middleman is scheduled to debut in 2020.

By Jacob Bell • Oct. 18, 2017

Lilly taps CureVac for mRNA cancer drugs

The deal, worth almost $2 billion all told, validates CureVac's mRNA technology. 

By Lisa LaMotta • Oct. 18, 2017

Biopharma, medical M&A activity slows in 2017: report

Despite some big ticket transactions, global deal count and value have ticked down so far this year, according to a Mergermarket analysis. 

By Lisa LaMotta • Oct. 17, 2017

Amneal, Impax combine amid generics crunch

Together, the two companies will rank as the fifth-largest generics maker in the U.S. by gross revenue. 

By Ned Pagliarulo • Oct. 17, 2017

Financial woes trigger layoffs at Biostage

After a private placement deal went south, Biostage said it would cut 70% of staff in a move to stay solvent as it evaluates its options. 

By Suzanne Elvidge • Oct. 16, 2017

Roche kicks antibiotic development into Warp Drive

Through a deal with Warp Drive Bio, the Swiss drugmaker is looking to advance novel drugs at a time when antibiotic resistance is raising serious alarms.

By Jacob Bell • Oct. 16, 2017

Prescribed Reading: A week of game-changers in pharma

A new gene therapy is poised to hit the market; one dose of Anaptysbio's drug is all it took to clear some patients' skin; and a late-stage failure is hurting Lilly's oncology prospects.

By Lisa LaMotta • Oct. 13, 2017

SINE of the times: Karyopharm taps Ono for Asian market

The regional deal gives Ono the rights to Karyopharm's lead asset Selinexor and other cancer assets in certain parts of the world. 

By Suzanne Elvidge • Oct. 13, 2017

Merck invests in diabetes through KalVista deal

By taking a stake in KalVista, the big pharma aims to buffer its diabetes franchise with related therapies. 

By Lisa LaMotta • Oct. 11, 2017

Express Scripts drops $3.6B for healthcare management company

The PBM said this latest acquisition furthers its "goal of becoming the nation's leading patient benefit manager."

By Jacob Bell • Oct. 10, 2017

Pfizer mulls sale of consumer health business

A potential sale of the unit, which includes brands like Advil and Centrum, would allow Pfizer to focus resources on its higher-earning pharma division. 

By Lisa LaMotta • Oct. 10, 2017

AbbVie solidifies its I/O pipeline with Turnstone deal

A new agreement hands AbbVie the option to exclusively license up to three oncolytic viral immunotherapies.

By Jacob Bell • Oct. 10, 2017

Prescribed Reading: DMD, MS and other acronyms

Another DMD drug struggles to get closer to market, a blockbuster MS drug now faces multiple generic competitors, and a deal is inked to increase competition in the Tyk2 inhibitor space. 

By Lisa LaMotta • Oct. 6, 2017